GlassScriptPhysician profile
Ibrahim Kassas
NPI 1629366406
$17,292.22
in general payments reported to CMS, 2019-2025
33 companies · $3,002 in 2025
The $3,002 reported for 2025 was more than what 75% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,992 · 2020: $64.36 · 2021: $625 · 2022: $2,194 · 2023: $2,072 · 2024: $4,344 · 2025: $3,002.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,098 · Travel and Lodging: $4,031 · Consulting Fee: $1,250 · Entertainment: $38.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,098.42 |
| Travel and Lodging | $4,030.71 |
| Consulting Fee | $1,250.00 |
| Entertainment | $38.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $4,917.87 | 2019-2025 | Pascal, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Abbott Laboratories | $4,619.97 | 2019-2025 | Mitraclip |
| Boston Scientific Corporation | $3,141.06 | 2019-2025 | Watchman Flx, Watchman, Watchman Access System |
| Medtronic Vascular, INC. | $1,551.61 | 2019 | |
| Medtronic, INC. | $312.70 | 2021-2025 | Corevalve Evolut R, Venaseal, Onyx Frontier |
| Novo Nordisk INC | $286.59 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $279.93 | 2022-2025 | |
| Cardiva Medical, INC. | $254.60 | 2024-2025 | Savvywire, Cardiva Vascade 6/7f Vcs, Optowire |
| Teleflex LLC | $196.57 | 2022-2025 | Supercross |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.36 | 2022-2025 | Jardiance |
| Inspire Medical Systems, INC. | $165.50 | 2025 | Inspire |
| Penumbra, INC. | $145.01 | 2024 | Indigo System |
| Astrazeneca Pharmaceuticals LP | $125.23 | 2021-2023 | Brilinta |
| Pfizer INC. | $116.97 | 2023-2025 | |
| Atricure, INC. | $113.85 | 2024-2025 | Epi-Sense Guided Coagulation System With Visitrax |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $112.76 | 2020-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $100.37 | 2021-2025 | Camzyos, Eliquis |
| Heartflow, INC. | $100.15 | 2024-2025 | |
| Abiomed | $95.98 | 2024 | Impella |
| Amgen INC. | $62.68 | 2021-2025 | Repatha, Repatha |
| Terumo Medical Corporation | $48.85 | 2019-2022 | |
| Esperion Therapeutics, INC. | $46.72 | 2021-2022 | |
| Philips North America LLC | $45.36 | 2024 | (Ao0) Igt Devices Intracardiac |
| Imperative Care, INC | $43.80 | 2024-2025 | Symphony Catheter |
| Opsens INC. | $38.29 | 2023 | Optowire |
| Abbvie INC. | $33.79 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $31.38 | 2021 | |
| Janssen Pharmaceuticals, INC | $30.23 | 2019-2021 | |
| Shockwave Medical, INC | $22.72 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Angiodynamics, INC. | $22.12 | 2025 | Alphavac |
| Cordis US Corp. | $15.79 | 2025 | Mynx Control Venous |
| Jubilant Draximage INC. | $13.77 | 2022 | |
| Cvrx, INC. | $8.64 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ibrahim Kassas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.